



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Thiazolidinediones (TZDs) and TZD Combination Drugs

Policy # 00362

Original Effective Date: 09/18/2013

Current Effective Date: 09/17/2014

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider brand name thiazolidinediones (TZDs) and brand name thiazolidinedione (TZD) combination drugs (including, but not limited to Actos® [pioglitazone], Actoplus Met® [pioglitazone/metformin], Duetact® [pioglitazone/glimepride], Avandia® [rosiglitazone], Avandamet® [rosiglitazone/metformin], and Avandaryl® [rosiglitazone/glimepride])[‡] to be **eligible for coverage** when one of the patient selection criteria below is met:

Patient Selection Criteria

Coverage eligibility will be considered for brand name thiazolidinediones (TZDs) or brand name thiazolidinedione (TZD) combination drugs when one of the following criteria is met:

- Patient has tried metformin or a metformin containing product (brand or generic) OR a generic thiazolidinedione (TZD) or a generic thiazolidinedione (TZD) containing product (e.g. pioglitazone, pioglitazone/metformin); OR
- There is clinical evidence or patient history that suggests that metformin products or generically available thiazolidinedione (TZD) products will be ineffective or cause an adverse reaction to the patient.

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of brand name thiazolidinediones (TZDs) or brand name thiazolidinedione (TZD) combination products when patient selection criteria are not met or for usage not included in the above patient selection criteria to be **not medically necessary.****

Background/Overview

Thiazolidinediones and TZD combination products are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Package insert indications vary depending on the chosen TZD.

Rationale/Source

The patient selection criteria presented in this policy takes into consideration clinical evidence or patient history that suggests metformin products or generic TZD products will be ineffective or cause an adverse reaction to the patient. Based on a review of the data, in the absence of the above mentioned caveats, there is no advantage of using a brand name TZD or brand name TZD combination product over the available metformin products OR generic TZD products. Generic drugs are considered to have equal bioavailability and efficacy in comparison to brand name drugs.

©2014 Blue Cross and Blue Shield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Thiazolidinediones (TZDs) and TZD Combination Drugs

Policy # 00362

Original Effective Date: 09/18/2013

Current Effective Date: 09/17/2014

References

1. Glucophage® tablets/Glucophage® XR extended-release tablets [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; April 2011.
2. Glumetza® extended release tablets [package insert]. Menlo Park, CA: Depomed, Inc.; April 2011.
3. Fortamet® extended release tablets [package insert]. Atlanta, GA: Sciele Pharma, Inc.; February 2010.
4. Riomet oral® solution [package insert]. Jacksonville, FL: Ranbaxy Pharmaceuticals; June 2010.
5. Avandia® tablets [package insert]. Research Triangle Park, NC: GlaxoSmithKline; May 2011.
6. Actos® tablets [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; January 2012.
7. Avandamet® tablets [package insert]. Research Triangle Park, NC: GlaxoSmithKline; May 2011.
8. Actoplus Met® [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc. May 2012.
9. Duetact™ tablets [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; July 2011.
10. Avandaryl™ tablets [package insert]. Research Triangle Park, NC: GlaxoSmithKline; December May 2011.
11. FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-containing Medicines including Avandia, Avandamet, and Avandaryl. May 18, 2011. Accessed October 9, 2012. 3, 2011. Available at: <http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm>.
12. Jentadueto™ tablets [package insert]. Ridgefield, CT: Boehringer Ingelheim; January 2012.
13. Kombiglyze™ XR tablets [package insert]. Princeton, NJ: Bristol-Meyers Squibb Company; March 2012.
14. Janumet® XR tablets [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; April 2012.
15. American Diabetes Association. Standard of Medical Care in Diabetes. *Diabetes Care*. 2012;35(1):S11-S63.
16. Inzucchi SE, Bergenfelz RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patients centered approach. Position statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2012;35(6):1364-79.
17. Handelsman Y, Mechanick JL, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. *Endocr Pract*. 2011;17(Supple 2):1-53.
18. Bennett WL, Wilson LM, Bolen S, et al. Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update. Comparative Effectiveness Review No. 27. (Prepared by Johns Hopkins University Evidence-based Practice Center under Contract No. 290-02-0018.) AHRQ Publication No. 11-EHC038-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2011. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.
19. Robard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. *Endocr Pract*. 2009;15(6):540-559.
20. Actoplus Met® XR tablets [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc. July 2011.
21. Kazano™ tablets [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; January 2013

Policy History

Original Effective Date: 09/18/2013

Current Effective Date: 09/17/2014

09/05/2013 Medical Policy Committee review

09/18/2013 Medical Policy Implementation Committee approval. New policy.

09/04/2014 Medical Policy Committee review

09/17/2014 Medical Policy Implementation Committee approval. No change to coverage.

Next Scheduled Review Date: 09/2015

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means



BlueCross BlueShield of Louisiana

An independent licensee of the Blue Cross and Blue Shield Association.

Thiazolidinediones (TZDs) and TZD Combination Drugs

Policy # 00362

Original Effective Date: 09/18/2013

Current Effective Date: 09/17/2014

of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or "Medical Necessity") - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.